

Statement of Unaudited Results for the Quarter ended 30th June, 2012

[₹ in Lacs]

STAND ALONE RESULTS				Particulars	CONSOLIDATED RESULTS			
Quarter Ended		Year Ended			Quarter Ended		Year Ended	
June 30	March 31	June 30	March 31		June 30	March 31	June 30	March 31
(Unaudited)	(Audited)	(Unaudited)	(Audited)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
2012	2012	2011	2012		2012	2012	2011	2012
PART I								
73682	69356	61490	261764	Income from operations	123589	117110	94187	425395
575	723	476	2343	a) Net sales/Income from operations (Net of excise duty)	441	3319	845	4918
74257	70079	61966	264107	b) Other Operating Income	124030	120429	95032	430313
65813	67773	52296	236145	Total income from operations (net)	102570	102675	81241	364604
35361	31919	28455	123995	Expenses	43278	38094	33578	149469
4727	5287	5706	24368	a) Cost of material consumed	7593	9233	6787	32327
(1718)	546	(2217)	(9326)	b) Purchase of traded goods	(3609)	(825)	(4201)	(20009)
8369	8719	5544	26976	c) Change in inventories of finished goods, work-in-progress and traded goods	8599	8304	6001	27876
5608	5349	4678	20723	d) Power & fuel	23143	21241	18976	83637
3607	4283	2768	13200	e) Employee benefits expenses	5906	6619	4977	22065
9859	11670	7362	36209	f) Depreciation & amortization expenses	17660	20009	15123	69239
8444	2306	9670	27962	g) Other expenses	21460	17754	13791	65709
174	241	235	894	Profit/(Loss) from operations before other income, finance cost and exceptional items	308	471	244	1529
8618	2547	9905	28856	Other Income	21768	18225	14035	67238
4505	4552	3003	15442	Profit/(Loss) from ordinary activities before finance costs & exceptional items	5934	5855	4362	20959
4113	(2005)	6902	13414	Finance costs	15834	12370	9673	46279
10424	(1742)	268	18008	Profit/(Loss) from ordinary activities after finance costs but before exceptional items	10424	14641	418	34868
(6311)	(263)	6634	(4594)	Exceptional items	5410	(2271)	9255	11411
1049	15	1245	3497	Profit/(Loss) from ordinary activities before tax	3887	3508	1516	6842
(7360)	(278)	5389	(8091)	Tax expense (Net)	1523	(5779)	7739	4569
-	-	-	-	Net Profit/(Loss) from ordinary activities after tax	-	-	-	-
(7360)	(278)	5389	(8091)	Extraordinary items (net of tax expenses)	1523	(5779)	7739	4569
-	-	-	-	Net Profit/(Loss) for the period	-	-	-	-
(7360)	(278)	5389	(8091)	Share of Profit/(Loss) of Associate Company	1022	574	27	3113
-	-	-	-	Minority Interest	501	(6353)	7712	1456
1593	1593	1593	1593	Net Profit/(Loss) after taxes, minority interest and share of profit/loss of associates	1593	1593	1593	1593
-	-	-	-	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593
-	-	-	-	Reserves (excluding revaluation reserve)	-	-	-	-
-	-	-	-	Earnings per share before and after extraordinary items (Not annualized)	-	-	-	-
(4.62)	(0.17)	3.38	(5.08)	Basic (₹)	0.31	(3.99)	4.84	0.91
(4.62)	(0.17)	3.38	(5.08)	Diluted (₹)	0.31	(3.99)	4.84	0.91
PART II								
PARTICULARS OF SHAREHOLDING								
81166083	81166083	84129115	81166083	Public shareholding	81166083	81166083	84129115	81166083
50.96	50.96	52.82	50.96	- Number of shares (₹ 1 each)	50.96	50.96	52.82	50.96
-	-	-	-	- Percentage of shareholding	-	-	-	-
Promoters and promoter group Shareholding								
a) Pledged/Encumbered								
3374000	3374000	7887333	3374000	- Number of shares	3374000	3374000	7887333	3374000
4.32	4.32	10.50	4.32	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	4.32	4.32	10.50	4.32
2.12	2.12	4.95	2.12	- Percentage of shares (as a % of the total share capital of the company)	2.12	2.12	4.95	2.12
b) Non-Encumbered								
74741056	74741056	67264691	74741056	- Number of shares	74741056	74741056	67264691	74741056
95.68	95.68	89.50	95.68	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	95.68	95.68	89.50	95.68
46.92	46.92	42.23	46.92	- Percentage of shares (as a % of the total share capital of the company)	46.92	46.92	42.23	46.92
Investor Complaints								
Pending at the beginning of the quarter				Nil				
Received during the quarter				4				
Disposed of during the quarter				4				
Remaining unresolved at the end of the quarter				Nil				

Segment wise Revenue, Results and Capital Employed

(under Clause 41 of the Listing Agreement)

[₹ in Lacs]

STAND ALONE RESULTS				Particulars	CONSOLIDATED RESULTS			
Quarter Ended		Year Ended			Quarter Ended		Year Ended	
June 30	March 31	June 30	March 31		June 30	March 31	June 30	March 31
(Unaudited)	(Audited)	(Unaudited)	(Audited)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
2012	2012	2011	2012		2012	2012	2011	2012
Segment revenue								
17241	16776	11305	56811	a. Pharmaceuticals	64124	64626	44148	220131
57084	53361	50756	207602	b. Life Sciences Ingredients	59974	55861	50979	210488
74325	70137	62061	264413	Total	124098	120487	95127	430619
68	58	95	306	Less : Inter segment revenue	68	58	95	306
74257	70079	61966	264107	Net Sales/Income from operations	124030	120429	95032	430313
17241	16776	11305	56811	a. Pharmaceuticals	64124	64626	44148	220131
57016	53303	50661	207296	b. Life Sciences Ingredients	59906	55803	50884	210182
74257	70079	61966	264107	Total	124030	120429	95032	430313
Segment results (profit+)/loss(-) before tax and interest from each segment								
4313	2665	1184	10032	a. Pharmaceuticals	16431	17192	5193	47088
7862	1381	10205	25612	b. Life Sciences Ingredients	8760	2301	10339	26302
12175	4046	11389	35644	Total	25191	19493	15532	73390
4505	4552	3003	15442	Less : i. Interest (Finance costs)	5934	5855	4362	20959
14155	(2)	1987	25690	ii. Other un-allocable expenditure (including exceptional items)	14155	16380	2159	42549
(174)	(241)	(235)	(894)	iii. Un-allocable Income (including exceptional items)	(308)	(471)	(244)	(1529)
(6311)	(263)	6634	(4594)	Total profit/(loss) before tax	5410	(2271)	9255	11411
Capital Employed (Segment assets less Segment liabilities)								
94961	90475	84372	90475	a. Pharmaceuticals	450398	417359	386038	417359
167253	162059	161571	162059	b. Life Sciences Ingredients	183674	174624	172325	174624
262214	252534	245943	252534	Total capital employed in segments	634072	591983	558363	591983
245702	261221	232696	261221	Add: Un-allocable corporate assets less liabilities	35955	51154	25823	51154
507916	513755	478639	513755	Total capital employed in the Company	670027	643137	584186	643137

Notes:

- In order to provide better understanding of nature of business lines and operating matrix the Company has identified two reportable segment as i) Pharmaceuticals and ii) Life Sciences Ingredients effective current quarter. The Pharmaceutical Segment comprises of Active Pharmaceutical Ingredients, Generics, Speciality Pharma, Contract Manufacturing of Sterile and Non Sterile Products, Drug Discovery and Development Solutions and Healthcare business and Life Sciences Ingredients Segment comprises of Proprietary Products and Exclusive Synthesis, Nutrition Ingredients and Life Sciences Chemical business.
- The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 "The Effects of Changes in Foreign Exchange Rates". Accordingly exchange differences amounting to ₹ 1678 lacs has been amortized during the quarter and the accumulated debit balance in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) is ₹ 13435 lacs as at 30th June, to be amortized over the balance life of the respective loan and ₹ 2367 lacs has been debited to Capital Work in Progress.
- The company has applied hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered accountants of India and the debit balance in hedge reserve as at 30th June, 2012 is ₹ 8379 lacs (Consolidated ₹ 9112 lacs).
- Exceptional items include :
 - Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 1678 lacs (Consolidated ₹ 1678 lacs) for Q1-FY 2013.
 - Mark to Market in respect of Currency & Interest rate swap contracts at the quarter end resulting in loss/(gain) amounting to ₹ 8746 lacs (Consolidated ₹ 8746 lacs) for Q1 FY 2013.
- Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement.
- Previous year / periods figures have been regrouped/reclassified wherever necessary.
- The above un-audited results were, subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 23rd July, 2012.

For Jubilant Life Sciences Limited

Place : Noida
Date : 23rd July, 2012

Shyam S Bhartia
Chairman & Managing Director